XML 72 R51.htm IDEA: XBRL DOCUMENT v3.25.4

Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Sales by Significant Product Group

The following table presents net sales information about our reportable segments, reconciled to consolidated totals:

($ in millions)			2025						2024						2023
Net sales:
Proprietary Products			$	2,492.1					$	2,334.5					$	2,397.3
Contract-Manufactured Products			582.0						558.7						552.5
Consolidated net sales			$	3,074.1					$	2,893.2					$	2,949.8

Schedule of Sales and Long-Lived Assets, by Geographical Areas

The following table presents net sales and long-lived assets, by the country in which the legal subsidiary is domiciled and assets are located:

			Net Sales																		Long-Lived Assets
($ in millions)			2025						2024						2023						2025						2024
United States			$	1,329.6					$	1,230.8					$	1,238.5					$	834.7					$	832.0
Germany			380.3						372.5						406.1						233.2						191.1
Ireland			333.3						323.2						285.7						366.3						299.6
France			226.6						242.2						282.9						113.3						84.7
Other European countries			451.0						385.5						388.1						108.7						98.1
Other			353.3						339.0						348.5						221.9						210.3
			$	3,074.1					$	2,893.2					$	2,949.8					$	1,878.1					$	1,715.8

Schedule of Segment Reporting Information, by Segment

			2025																		2024																		2023
($ in millions)			Proprietary Products						Contract- Manufactured Products						Total						Proprietary Products						Contract- Manufactured Products						Total						Proprietary Products						Contract- Manufactured Products						Total
Net sales			$	2,492.1					$	582.0					$	3,074.1					$	2,334.5					$	558.7					$	2,893.2					$	2,397.3					$	552.5					$	2,949.8
Cost of goods and services sold			1,483.9						486.2												1,434.0						460.7												1,363.3						456.5
Research and development			74.3						—												69.1						—												68.4						—
Selling, general and administrative expenses			255.6						29.9												231.5						26.2												240.6						24.4
Other segment expense (income)(1)			21.1						2.5												22.1						(0.5)												14.9						(0.5)
Segment operating profit			$	657.2					$	63.4					$	720.6					$	577.8					$	72.3					$	650.1					$	710.1					$	72.1					$	782.2
Reconciliation of profit or loss:
Stock-based compensation															(23.8)																		(18.7)																		(23.3)
Corporate general costs(2)															(74.4)																		(58.6)																		(68.3)
Unallocated items:
Restructuring and other charges(3)															(23.3)																		(2.1)																		2.0
SmartDose® 3.5mL sale(4)															(8.4)																		—																		—
Cost-method investment activity(5)															(4.5)																		—																		(4.3)
Amortization of acquisition-related intangible assets(6)															(0.2)																		(0.8)																		(0.7)
Other															(1.1)																		—																		—
Loss on disposal of plant(7)															—																		—																		(11.6)
Total corporate and unallocated items															(135.7)																		(80.2)																		(106.2)
Total consolidated operating profit															584.9																		569.9																		676.0
Interest (income) expense and other nonoperating expense (income), net															(16.0)																		(15.6)																		(22.0)
Income before income taxes and equity in net income of affiliated companies															$	600.9																	$	585.5																	$	698.0

(1) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and asset impairments attributable to the segments during the periods ended December 31, 2025, 2024 and 2023.

(2) Corporate general costs includes executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(3) During 2025, the Company recorded charges of $23.3 million related to our two existing restructuring programs: (i) $18.4 million of the charges within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $4.9 million within selling, general and administrative expenses, for professional services related to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. During 2024, the Company recorded expense to restructuring and other charges of $2.1 million. The net expense represents the impact of two items, the first of which is $4.6 million of expense recorded within selling, general and administrative expenses in connection with a plan to optimize the legal structure of the Company and its subsidiaries. The expense consists primarily of consulting fees, legal expenses, and other one-time costs directly attributable to this plan. This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan. During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold.

(4) During 2025, the Company recorded charges of $8.4 million related to the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $6.2 million of the charges within other expense (income), related to severance and lease impairment charges in connection with the sale agreement. The Company recorded the remaining $2.2 million within selling, general and administrative expenses, relating to professional services in connection with the sale agreement.

(5) During 2025, the Company recorded cost-method investment impairment charges of $4.5 million within other expense (income). During 2023, the Company recorded cost-method investment impairment charges of $4.3 million within other expense (income).

(6) During 2025, 2024 and 2023, the company recorded $0.2 million, $0.8 million and $0.7 million, respectively, of amortization expense within selling, general and administrative expenses associated with an acquisition of an intangible asset during the second quarter of 2020.

(7) During 2023, the Company recorded expense of $11.6 million within other expense (income) as a result of the sale of one of the Company’s manufacturing facilities within the Proprietary Products segment. The transaction closed during the second quarter of 2023.

The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:

($ in millions)
Assets			2025						2024
Proprietary Products			$	2,987.0					$	2,621.1
Contract-Manufactured Products			718.1						612.2
Corporate and Unallocated(1)			564.9						410.1
Total consolidated			$	4,270.0					$	3,643.4

(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.

($ in millions)
Depreciation and Amortization			2025						2024						2023
Proprietary Products			$	140.2					$	130.3					$	112.9
Contract-Manufactured Products			27.9						21.3						20.4
Corporate and Unallocated			3.3						3.8						4.0
Total consolidated			$	171.4					$	155.4					$	137.3

($ in millions)
Capital Expenditures			2025						2024						2023
Proprietary Products			$	204.3					$	246.5					$	259.1
Contract-Manufactured Products			75.5						121.0						90.2
Corporate and Unallocated			6.1						9.5						12.7
Total consolidated			$	285.9					$	377.0					$	362.0

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration